Management of Diffuse Pontine Gliomas in Children: Recent Developments
Authors:
- 30 May 2013
- journal article
- review article
- Published by Springer Nature in Pediatric Drugs
- Vol. 15 (5) , 351-362
Abstract
The prognosis for children with diffuse intrinsic pontine gliomas (DIPGs) is dismal. Although DIPGs constitute only 10–15 % of all pediatric brain tumors, they are the main cause of death in this group with a median survival of less than 12 months. Standard therapy involves radiotherapy, which produces transient neurologic improvement. Despite several clinical trials having been conducted, including trials on targeted agents to assess their efficacy, there is no clear improvement in prognosis. However, knowledge of DIPG biology is increasing, mainly as a result of research using biopsy and autopsy samples. In this review, we discuss recent studies in which systemic therapy was administered prior to, concomitantly with, or after radiotherapy. The discussion also includes novel therapeutic options in DIPG. Continuing multimodal and multitargeted therapies might lead to an improvement in the dismal prognosis of the disease.Keywords
This publication has 74 references indexed in Scilit:
- Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experienceJournal of Neuro-Oncology, 2011
- Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology GroupNeuro-Oncology, 2011
- Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomasNeuro-Oncology, 2011
- A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor ConsortiumNeuro-Oncology, 2011
- A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomasEuropean Journal of Cancer, 2010
- Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsNeuro-Oncology, 2010
- Bevacizumab in recurrent high-grade pediatric gliomasNeuro-Oncology, 2010
- Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade GliomaClinical Cancer Research, 2009
- Aurora B expression correlates with aggressive behaviour in glioblastoma multiformeJournal of Clinical Pathology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005